Search results for:
Ondine reports full results from Phase 2 nasal photodisinfection trial
Ondine Biomedical reports the full results from Phase 2 nasal photodisinfection trial Vancouver, British Columbia, Canada - December 5, 2022 Full results confirm that a single, 5-minute treatment of nasal photodisinfection significantly reduces Staphylococcus aureus, a major cause of surgical site infections, in pre-surgical patients. [...]
Ondine presents new efficacy data against MRSA
Ondine Biomedical presents research showing its Steriwave photodisinfection treatment is highly effective against multidrug-resistant strains of MRSA Vancouver, British Columbia, Canada - October 19, 2022 Photodisinfection technology shows great promise as a new method for fighting drug-resistant infections amidst rising rates of antimicrobial resistance. Ondine [...]
Steriwave™ cuts SSI risk by 47% at major hospital
New study shows nasal photodisinfection cuts surgical site infection risk by 47% and mortality by nearly 60% Vancouver, British Columbia, Canada - October 19, 2022 Surgical site infections reduced by an average of 47% across all surgery types (P=0.01). Most significant impact seen in cardiac [...]
The Ottawa Hospital pilots pre-surgical nasal disinfection
The Ottawa Hospital pilots pre-surgical nasal disinfection for all spine surgery patients to reduce infections Vancouver, British Columbia, Canada - September 23, 2022 The Ottawa Hospital has chosen to use photodisinfection technology developed by Canadian life sciences company, Ondine Biomedical. Nasal decolonization has been recommended [...]
Photodisinfection successfully eradicates pathogens associated with replacement joint infections
New research shows photodisinfection successfully eradicates pathogens associated with replacement joint infections Vancouver, British Columbia, Canada - September 20, 2022 A research team in Zurich, Switzerland has presented results from an in vitro study showing that photodisinfection achieved >99.99% eradication (4-7 log10 kill) of the [...]
Ondine’s photodisinfection kills ESKAPE pathogens
Data presented at World AMR Congress shows Ondine Biomedical’s photodisinfection effective against antibiotic-resistant ESKAPE pathogens Vancouver, British Columbia, Canada - September 7, 2022 Canadian life sciences company, Ondine Biomedical Inc. (LON: OBI), this week presented an in vitro study at the World Anti-Microbial Resistance [...]
Ondine reports successful US Phase 2 trial data
Ondine Biomedical reports successful topline data from Phase 2 nasal photodisinfection trial Vancouver, British Columbia, Canada - September 6, 2022 Results show a single, 5-minute treatment of nasal photodisinfection significantly reduces Staphylococcus aureus, a major cause of surgical site infections, in pre-surgical patients Top line results [...]
Nature publication: Ondine’s therapy suppresses SARS2 in COVID-19 patients
Nature publication reports that Ondine’s nasal antimicrobial photodynamic disinfection therapy suppresses SARS-CoV-2 in COVID-19 patients Vancouver, British Columbia, Canada - August 31, 2022 The Toronto-based research reports a decrease of viral infectivity of 90% of SARS-CoV-2 patient samples using Ondine’s nasal antimicrobial photodynamic disinfection (aPDT), [...]
Ondine completes enrollment for US Phase II nasal photodisinfection trial
Ondine Biomedical completes patient recruitment for US Phase II nasal photodisinfection trial Vancouver, British Columbia, Canada - August 8, 2022 Ondine Biomedical Inc. (LON: OBI), has recruited the final patient to its nasal photodisinfection exploratory Phase 2 trial. The trial is evaluating how effectively Ondine’s [...]
Successful SARS-CoV-2 trial with Ondine’s nasal photodisinfection
Suppression of SARS-CoV-2 replication and infectivity in vaccinated individuals: a clinical study of Ondine Biomedical’s nasal photodisinfection carried out at the Clínica Universidad de Navarra, Spain Vancouver, British Columbia, Canada - July 19, 2022 Clínica Universidad de Navarra has completed a randomised controlled study of Ondine [...]
For Media Information
Simon Vane Percy
Amanda Bernard
